News | August 19, 2024
CIDSCON 2024 discusses actionable efforts to tackle antimicrobial resistance
The emergence of new infections in India is a growing concern
The emergence of new infections in India is a growing concern
The company is also looking at an inorganic opportunity over the next two years to have a commercially ready footprint in the US
This two-day program was attended by 40 doctors & paramedical staff
India Business grew by 11.9% YoY to Rs. 1196.2 crore
The clinical trial will be conducted at 19 sites with 10,335 participants across India
Majority of organizations are looking to increase investments in public and hybrid cloud
Gross profit was Rs. 328.8 crore, up by 27.8% YoY with a gross margin expansion of 418 bps to 55.7%
He recently served as Senior Vice President of the API business at Shilpa Pharma Life Sciences for over 3 years
Capital expenditure expected to moderate to Rs. 5.6 billion in FY2025 from an estimated Rs. 7.6 billion in FY2024
European markets now contribute 51% of our business revenue up from 43% in Q4 FY24 and 34% in Q1 FY24
Subscribe To Our Newsletter & Stay Updated
